| 000 | 01584 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516131519.0 | ||
| 264 | 0 | _c20130820 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1523-1755 | ||
| 024 | 7 |
_a10.1038/ki.2012.444 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMunyentwali, Helene | |
| 245 | 0 | 0 |
_aRituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. _h[electronic resource] |
| 260 |
_bKidney international _cMar 2013 |
||
| 300 |
_a511-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadverse effects |
| 650 | 0 | 4 |
_aAntigens, CD19 _xanalysis |
| 650 | 0 | 4 |
_aAntigens, CD20 _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNephrosis, Lipoid _xdrug therapy |
| 650 | 0 | 4 |
_aPrednisone _xtherapeutic use |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aBouachi, Khedidja | |
| 700 | 1 | _aAudard, Vincent | |
| 700 | 1 | _aRemy, Philippe | |
| 700 | 1 | _aLang, Philippe | |
| 700 | 1 | _aMojaat, Rachid | |
| 700 | 1 | _aDeschênes, Georges | |
| 700 | 1 | _aRonco, Pierre M | |
| 700 | 1 | _aPlaisier, Emmanuelle M | |
| 700 | 1 | _aDahan, Karine Y | |
| 773 | 0 |
_tKidney international _gvol. 83 _gno. 3 _gp. 511-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/ki.2012.444 _zAvailable from publisher's website |
| 999 |
_c22424480 _d22424480 |
||